Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL, APO2L) has been shown to induce apoptosis in a number of tumor cell lines as well as in some primary tumors whereas cells from most normal tissues are highly resistant to TRAIL-induced apoptosis. We have studied the susceptibility of primary malignant and normal bone marrow hematopoietic progenitors to TRAIL-induced apoptosis. Extracellular domain of human TRAIL with N-terminal His 6 tag (His-TRAIL, amino acids 95-281) was produced in E. coli and its apoptosisinducing ability was compared with the leucine-zipper containing TRAIL, LZ-TRAIL. Both variants of TRAIL had the same apoptosis-inducing ability. Clonogenic progenitor assays showed that His-TRAIL significantly reduced the number of myeloid colonies (CFU-GM) and clusters from patients with acute myeloid leukemia (AML), chronic myeloid leukemia (CML), and myelodysplastic syndromes (MDS). His-TRAIL had no negative effect on the number of CFU-GM colonies and clusters derived from bone marrow cells of AML patients in complete remission, and lymphoma patients without bone marrow involvement, as well as those derived from normal cord blood cells. Moreover, we found that normal human stem cells treated with high doses of His-TRAIL maintain a repopulating potential when transplanted into NOD/SCID mice. To conclude, our data document that TRAIL does not affect normal human hematopoiesis but suppresses the growth of early primary leukemia and myelodysplasia progenitors. Leukemia (2002) 16, 67-73.
Introduction
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL, APO2L) is a potent inducer of tumor-specific apoptosis in vitro and in vivo. Many tumor cell lines as well as primary tumor cells are sensitive to TRAIL whereas normal cells are generally resistant. [1] [2] [3] In vivo, TRAIL was also effective against human-derived solid tumors transplanted into mouse recipients, and thus seems to have a potential use in the treatment of human malignant diseases. 4, 5 TRAIL-induced cell death requires the presence of apoptosis-inducing receptors and accessory post-receptor signaling molecules. Two types of TRAIL receptors are expressed on human cells: death-signaling receptors TRAIL-R1 (DR4) and TRAIL-R2 (DR5), and decoy receptors TRAIL-R3 (DcR1, TRID) and TRAIL-R4 (DcR2, TRUNDD). Decoy DcR1 and DcR2 are thought to function as inhibitors of TRAIL-induced signaling due to absent or truncated cytoplasmic 'deathdomain'. 6 TRAIL-activated death-signaling receptors DR4 and DR5 attract the adaptor molecules DAP3 and FADD that activate cleavage of pro-caspases 8 and 10. caspase-8 analog cFLIP inhibits TRAIL signaling by a competitive interaction with FADD. 11 Other molecules such as p53 regulate expression of TRAIL receptors and may change the ratio between apoptosis-signaling and decoy receptors. 12 Several cytotoxic drugs such as doxorubicine and etoposide also induce expression of TRAIL receptors, indicating that coadministration of TRAIL with these drugs may enhance tumor elimination. 13, 14 TRAIL is abundantly expressed on the surface of many cell types. 15 However, its physiological role is not yet fully understood. Zamai et al 16 suggested that TRAIL might also function together with Fas ligand as a negative regulator of normal erythropoiesis. In contrast, other authors reported that TRAIL did not induce apoptosis of normal human 'colony-forming unit granulocyte-macrophage' (CFU-GM) and 'burst-forming unit erythroid' (BFU-E) progenitors or CD34
dim early hematopoietic progenitors. 17 Engagement of TRAIL ligand by TRAIL receptors enhanced proliferation of TRAIL-expressing T cells and increased production of interferon gamma. 18 We have examined the effects of the human recombinant His-TRAIL on normal and leukemic hematopoiesis. Our data revealed that the human recombinant His-TRAIL suppressed in vitro growth of primary AML, CML and MDS progenitors, most probably through induction of their apoptosis. In contrast, normal hematopoietic repopulating stem cells and progenitors were resistant to its apoptosis-inducing activities and maintained their repopulating potential in NOD/SCID mice.
Materials and methods

Cloning, expression, purification of the extracellular domain of human TRAIL and detection of TRAILinduced apoptosis
The extracellular domain of human TRAIL (amino acids 95-281) was isolated by RT-PCR from HPB T cell line, sequence-verified and subcloned into E. coli expression plasmid containing N-terminal His 6 tag. His-TRAIL was expressed in E. coli BL-21 and purified by the sequential chromatography on TALON (Clontech, Palo Alto, CA, USA) and SPSepharose (Pharmacia, Peapack, NJ, USA). The purity of the recombinant His-TRAIL (Killer TRAIL, Alexis, San Diego, CA, USA) was determined by SDS-PAGE electrophoresis. Apoptosis-inducing ability of the recombinant His-TRAIL was tested on leukemic hematopoietic cell lines (including myeloid ML-1, TF-1 and HL-60, T cell lines Jurkat and CEM, and a B cell line, Daudi 
Cell lines
Hematopoietic cell lines K562, human erythroleukemia cell line (HEL), HL60, TF-1, Jurkat, Daudi, CEM, and ML1 (ATCC, Manassas, VA, USA) were cultured in the presence of 10% fetal bovine serum (FBS) (Life Technologies, Gaithersburg, MD, USA) in Iscove's modified Dulbecco's medium (IMDM) or RPMI (Sigma) and 5% CO 2 in a humidified atmosphere of 5% O 2 in air at 37°C. TF-1 required the addition of 10 ng/ml of human granulocyte-macrophage colony-stimulating factor (GM-CSF, Leukomax; Schering-Plough, Basel, Switzerland).
Cells from leukemia patients
Bone marrow (BM) cells were obtained with the informed consent of all patients from the remainder of BM aspirates obtained for routine diagnostic procedures. Cord blood cells (n = 6) were obtained from the Cord Blood Bank in Prague, a member of the Eurocord Project. All patients with acute myeloid leukemia (AML) (n = 36), chronic myeloid leukemia (CML) (n = 33), myelodysplastic syndrome (MDS) (n = 40), and non-Hodgkin's lymphoma (NHL) (n = 3) were diagnosed according to the European Organization for Research and Treatment of Cancer (EORTC) standard criteria. Cells from CML patients in the chronic phase were obtained either at the time of CML diagnosis or during ␣-interferon therapy. Cells from AML patients were obtained either at the time of diagnosis, in relapse or during complete hematologic remission.
Isolation of human CD34
+ cells
Human cord blood CD34 + cells were isolated using magnetic cell sorting (MACS; Miltenyi Biotec, Bergisch Gladbach, Germany) from the mononuclear cell population separated on Histopaque 1077 (Sigma) gradient. These cells were further analyzed by flow cytometry for the expression of CD34 + ; the percentage of CD34 + cells routinely exceeded 95%. All antibodies used for flow cytometry analyses were purchased either from Becton Dickinson (San Jose, CA, USA) or from Beckman Coulter (Fullerton, CA, USA).
Clonogenic assay
Standard 7-day agar cultures of unfractioned BM cells or cord blood mononuclear cells (2 × 10 4 /ml) were supplemented with 20% FBS, 5% 5637 human bladder carcinoma conditioned media and maintained in 5% CO 2 , 5% O 2 , 90% N 2 at 37°C. Colonies were scored as aggregates of greater than 40 cells per colony and clusters as aggregates of 5-40 cells. This growth assay clearly discriminates the leukemic nature of AML. 19 Methylcellulose (1.3%) 14-day cultures of mononuclear cord blood cells (2 × 10 4 /ml) were supplemented with 30% FBS in IMDM medium, erythropoietin (4 U/ml), and stem cell factor (50 ng/ml). His-TRAIL was used at a concentration of 1.5 g/ml, which effectively induced apoptosis in TRAILsensitive tumor cell lines and inhibited the growth of progenitors in clonogenic assays of AML patients. The duplicate BM samples were grown in 35-mm Petri dishes with or without His-TRAIL. Cells from patients were included in the study only when the number of CFU-GM colonies in each of the untreated duplicate sample was at least 20.
Repopulation of human hematopoiesis in NOD/SCID mice
Transplantation into non-obese diabetic/severe combined immunodeficiency (NOD/SCID) NOD/LtSz-Prkdc scid /J mice (The Jackson Laboratory, Bar Harbor, ME, USA) was achieved with 5 × 10 4 human CB CD34 + cells per animal injected into a tail vein of sublethally irradiated mice (300 cGy). The transplanted animals were injected with 6 g of human GM-CSF per mouse three times a week. Mice were handled according to the rules of the Institutional Review Board. Human hematopoiesis in mouse bone marrow was analyzed 6-8 weeks after transplantation using flow cytometry. 20 Bone marrow cells for flow cytometry were isolated from large bones by flushing them with the sterile PBS. As a negative control of repopulation bone marrow of either irradiated or non-irradiated nontransplanted mice was used.
Statistical analysis
Student's t-test was used in the statistical evaluation of the results. P value of less then 0.05 was considered to be significant. Individual samples were considered sensitive to TRAIL, if the inhibition of CFU-GM colony or cluster formation was below 2 standard deviations (s.d.) of the control sample.
Results
TRAIL-induced apoptosis in human leukemic cell lines
Apoptosis-inducing activity of the recombinant His-TRAIL was tested on TRAIL-sensitive myeloid cell line ML-1 and compared with the activity of the recombinant LZ-TRAIL. His-TRAIL induced apoptosis of ML-1 cells as efficiently as LZ-TRAIL (Figure 1a) . To demonstrate specificity of His-TRAIL action, we used neutralizing anti-TRAIL monoclonal antibody 2E5 to block TRAIL-induced apoptosis of ML-1 cells ( Figure  1b) . Several other hematopoietic cell lines were then treated with His-TRAIL (0.15 and 1.5 g/ml). Apoptosis was measured after 17 h and 3 days of incubation with or without His-TRAIL. HL60 cells that were previously found sensitive to LZ-TRAIL entered apoptosis in a dose-and time-dependent fashion (Figure 1c, 17) . DNA from HL60 cells at day 3 of the incubation with His-TRAIL was also analyzed in the DNA fragmentation assay. The extent of DNA laddering was dependent on the applied concentration of His-TRAIL (data not shown). Four other leukemic cell lines, CEM, Daudi, TF-1 and Jurkat, were also sensitive to His-TRAIL in a dose-dependent fashion (data not shown). Neither His-TRAIL nor LZ-TRAIL induced apoptosis of K562 erythroleukemia cells (Figure 1d and data not shown). 
Early leukemia progenitors are sensitive to TRAIL
Treatment of leukemia progenitors with His-TRAIL (1.5 g/ml) caused a significant decrease in a number of both myeloid CFU-GM colonies and clusters derived from CML, AML, and MDS patients (Figure 2 ). In contrast, the progenitors derived from AML patients during complete hematological remission (CR) (mean ± s.d., percent of CFU-GM survival, 91.5 ± 27.6%) were resistant to His-TRAIL as were the controls: lymphoma patients without bone marrow involvement and normal cord blood cells (99.8 ± 8.1%) (Figure 2 ). The growth of the CML progenitors in both chronic (CP) (58.1 ± 32.0%) as well as in accelerated or blastic phase (AC/BP) (51.8 ± 37.0%) of the disease, and overt AML (22.2 ± 20.7%) was significantly suppressed by the recombinant His-TRAIL. Moreover, progenitors derived from refractory anemia/refractory anemia with ringed sideroblast (RA/RARS) patients (66.3 ± 21.2%) and refractory anemia with excess of blasts/refractory anemia with excess of blasts in transformation (RAEB/RAEB-t) were also sensitive to His-TRAIL in vitro (Table 1 ). Compared to the normal controls which did not respond to His-TRAIL, we observed a wide range of sensitivity of tested myeloid leukemia and MDS patient progenitors in vitro. The growth of CML and MDS patient progenitor cells was overall less inhibited by His-TRAIL than growth of AML progenitors. These data demonstrated that His-TRAIL suppressed the growth of a large collection of primary leukemic and myelodysplastic progenitors whereas normal progenitors were resistant. Figure 3a shows that in vitro treatment of normal human CD34
Growth and differentiation of normal hematopoietic progenitors were not affected by TRAIL
+ cord blood cells with His-TRAIL (1.5 and 2 g/ml) did
Leukemia not affect the numbers of BFU-E-derived and CFU-GMderived colonies. Furthermore, flow cytometry analysis of the BFU-E and CFU-GM colony cells from His-TRAIL-treated (1.5 g/ml) and untreated semisolid cultures showed similarity between a proportion of erythroid (glycophorin-positive) and myeloid (CD14-positive) cells (Figure 3b ). It suggests that normal early erythroid and myeloid colony-forming progenitors were not affected by His-TRAIL in vitro. We also tested whether there was an increased sensitivity of terminally differentiated erythroid and myeloid precursors to His-TRAIL in vitro. BFU-E and CFU-GM colony cells were isolated from methylcellulose-based semisolid cultures at days 7-14 and were incubated with His-TRAIL for 17 h. By comparing the phenotypes and numbers of the cells we found that the terminally differentiated hematopoietic cells were not sensitive to His-TRAIL (data not shown).
Repopulating potential of normal hematopoietic stem cells was not affected by His-TRAIL
His-TRAIL has also been tested for its potential toxicity toward normal human hematopoietic stem cells. Flow cytometry analysis of several human cell surface receptors showed that human CD34 + cells treated with His-TRAIL repopulated hematopoiesis in mouse recipients (n = 5) comparably with nontreated controls (n = 3) (Figure 4 ). This suggests that normal stem cells were not affected by TRAIL. Both treated or untreated CD34
+ cells with TRAIL were not apoptotic prior to the transplantation as determined by annexin V/PI staining (data not shown). Thus, His-TRAIL did not affect the growth and differentiation of normal hematopoietic stem cells.
Figure 2
Early primary leukemia progenitors are sensitive to His-TRAIL. His-TRAIL (1.5 g/ml) significantly decreased the number of CFU-GM-derived colonies and clusters from patients with overt AML (n = 13), CML in chronic (CP) (n = 27) and accelerated (AC)/blastic (BP) phase (n = 6), and MDS -refractory anemia/refractory anemia with ringed sideroblasts (RA/RARS) (n = 22) or refractory anemia with excess of blasts/refractory anemia with excess of blasts in transformation (RAEB/RAEB-t) (n = 23). Cells from RAEB/RAEB-t patients did not produce a significant number of CFU-GM colonies, however, the number of clusters was high which is characteristic for this diagnosis. The cells derived from the normal human cord blood (CBC) (n = 6), AML patients in complete remission (CR) (n = 24) and lymphoma patients (NHL) without bone marrow involvement (n = 3) were resistant to His-TRAIL in the clonogenic CFU-GM agar-based assay. The percentage of growth survival (% of control) using the non-treated cultures as a control is shown (*, significant P Ͻ 0.01, **, P Ͻ 0.001, NS, non-significant P Ͼ 0.05, median values are shown by horizontal lines). The dashed lines represent 2 s.d. of the normal control cut-off level (16% for CFU-GM colonies, 27% for clusters), the hematopoietic progenitors that scored below this line were considered as sensitive to TRAIL. Data are expressed as average counts ± standard error of the mean. For further legend, see Figure 2 .
Discussion
Data from a number of recent in vitro and in vivo studies suggest that TRAIL could become a tumor-specific drug for malignant diseases. Recombinant TRAIL induces apoptosis in a number of transformed and primary tumor cells. [1] [2] [3] [4] Moreover, thyroid carcinomas and rhabdomyosarcomas that are resistant to FasL-induced apoptosis are highly sensitive to TRAILmediated apoptosis. 21, 22 Since a number of human cancer cell lines were sensitive to TRAIL in vitro, [1] [2] [3] [4] we examined the progenitor cells from primary leukemia and myelodysplasia patients for their sensitivity to TRAIL. TRAIL efficiently suppressed the numbers of CFU-GM colonies and clusters derived from AML, CML and MDS patients whereas relevant normal controls were resistant. The cells from patients with CML-AC/BP and overt AML appear to be more sensitive to TRAIL than cells from CML-CP and MDS-RA/RARS patients. His-TRAIL inhibited formation of CFU-GM colonies from CML-AP/BP and overt AML patients more frequently and to a higher extent than from CML-CP and MDS-RA/RARS patients. An explanation could be a higher proportion of malignant hematopoiesis in CML-AC/BP and overt AML patients. The growth (number) of CFU-GM colonies from patients with CML-CP was significantly suppressed by the recombinant TRAIL, although a wide range of responses was observed among individual patient progenitors (from 100% inhibition to none). This wide range of sensitivity to TRAIL could be explained either by additional, apoptosis-suppressing mutations in the malignant hematopoietic progenitors or by an effect of concurrent interferon therapy. 14, 23 An additional factor that would contribute to variations in the sensitivity of CML-CP progenitors to TRAIL could be remaining normal hematopoietic cells in the cell culture. Interestingly, the preleukemic MDS-RA/RARS progenitors were as sensitive to TRAIL-mediated growth suppression as the malignant hematopoietic leukemic progenitors. The resistance of progenitors from AML patients with complete remission could reflect normal hematopoiesis recovered in these patients.
The growth of hematopoietic progenitors in clusters (5-40 cells) reflects their leukemic nature. The ratio of number of clusters/CFU-GM colonies as well as the number of clusters is usually higher in myeloid leukemia with a high percentage of blast cells. 19 Cluster formation was significantly inhibited by TRAIL in CML-AC/BP and overt AML progenitors in a similar pattern, as was the inhibition of CFU-GM colonies. Interestingly, the growth of clusters of MDS-RAEB/RAEB-t progenitors was significantly inhibited by TRAIL within a wide
Figure 3
Normal hematopoietic progenitors were not affected by TRAIL. Normal human cord blood cells (CBC)-derived hematopoietic progenitors were resistant to His-TRAIL as determined by a clonogenic assay (a) and flow cytometry (b) of erythroid BFU-E and myeloid CFU-GM colonies derived from cord blood cells (n = 3, in duplicate). Results were expressed as mean ± standard deviation (**, significant P Ͻ 0.001, NS, non-significant P Ͼ 0.05).
range, suggesting heterogeneity of MDS-RAEB/RAEB-t cell population. Taken together, our data demonstrated that TRAIL induced apoptosis in leukemic cell lines and in a large collection of primary AML, CML and MDS progenitors.
Recent reports claimed the recombinant TRAIL-induced apoptosis of normal human hepatocytes and neurons. [24] [25] [26] In contrast, neither mouse nor primate organs were damaged by the in vivo administration of high doses of recombinant TRAIL. 1, 4 We examined two subpopulations of normal hematopoietic cells, repopulating stem cells and progenitors, for their sensitivity to TRAIL. Using in vitro (colony formation of progenitors) and in vivo (NOD/SCID mice model) assays we did not detect any deleterious effect of TRAIL on normal hematopoiesis. Thus, in agreement with others, 17 normal hematopoietic stem cells and progenitors survive treatment with a high concentration of TRAIL and therefore TRAIL could Leukemia be useful for purging of hematopoietic cells for autologous transplantation.
TRAIL may also function as a negative regulator of normal erythroid differentiation in later but not early stages of erythropoiesis. 16 Negative effect of TRAIL on erythroid progenitors in vitro was suppressed by a high concentration of erythropoietin (EPO). 16 In contrast, other authors reported that TRAIL did not induce apoptosis in normal human CFU-GM and BFU-E progenitors, or in sorted normal CD34 + /CD45 dim early hematopoietic progenitors. 17 We incubated normal erythroid progenitors with recombinant TRAIL and did not find any inhibition of growth or a decrease in the number of BFU-E (or CFU Normal hematopoietic stem cells were not affected by TRAIL. Normal human stem cells were resistant to His-TRAIL as assayed by transplantation of human cord blood CD34
+ cells preincubated for 17 h with and without TRAIL (1.5 g/ml) into NOD/SCID mice. The efficiency of repopulated hematopoiesis was determined by flow cytometry analysis of human CD45, glycophorin, CD14, CD20 and CD2 cell surface receptors. The results were expressed as mean ± standard error (NS, non-significant P Ͼ 0.05).
ony-forming erythroid progenitors were resistant to TRAIL. This observation could also be explained by an erythroid EPO production which triggered anti-apoptotic pathways. 27, 28 Insofar as the terminally differentiated erythroid and myeloid precursors were not sensitive to TRAIL in vitro, the role of TRAILmediated apoptosis in the negative regulation of red blood cell production is unlikely in contrast to FasL-mediated apoptosis.
We conclude that primary early AML, CML, and MDS hematopoietic progenitor cells were sensitive to TRAIL in vitro whereas normal hematopoietic repopulating stem cells, progenitors and precursors were resistant. Whether leukemia-initiating stem cells respond to TRAIL remains to be determined by further transplantation/repopulation studies of TRAILtreated progenitors in mouse recipients. These findings may have possible implications for the use of recombinant TRAIL in anti-leukemia and myelodysplasia therapeutic procedures.
